N⁶-methyladenosine-dependent primary microRNA-126 processing activated PI3K-AKT-mTOR pathway drove the development of pulmonary fibrosis induced by nanoscale carbon blac... by Bin Han (45760)

“…After CB treatment, PI3K-AKT-mTOR pathway was activated and regulated by miRNA-126. We found that both of m⁶A modifications of pri-miRNA-126 and its binding with DGCR8 were decreased after CB treatment, which resulted in the reduction of mature miRNA-126 accompanied by accumulation of unprocessed pri-miRNA-126. …”

Data_Sheet_5_Protective Effects of Magnesium Glycyrrhizinate on Methotrexate-Induced Hepatotoxicity and Intestinal Toxicity May Be by Reducing COX-2.PDF by Yuzhu Cao (732691)

Map of study area in the South Gondar region of northern Ethiopia. by Catherine L. Cardelús (6429320)

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot random... by Lívia Pimenta Bonifácio (7502579)

“…Sixty hospitalized patients with moderate-to-critical COVID-19 received in addition to standard of care (SOC): IL-17 inhibitor (ixekizumab 80 mg SC/week) 1 dose every 4 weeks; low-dose IL-2 (1.5 million IU per day) for 7 days or until discharge; or indirect IL-6 inhibitor (colchicine) orally (0.5 mg) every 8 hours for 3 days, followed by 4 weeks at 0.5 mg 2x/day; or SOC alone. …”

DataSheet_1_DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer.pdf by Xianneng Sheng (10076839)

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Results of t-tests comparing nutrient supply rates (micrograms / 10cm² / burial length) in sterilized versus live soil, in seedling pots. by Katherine E. A. Wood (17325907)

Table1_Comprehensive Analysis of Expression and Prognostic Value of MS4As in Glioma.DOCX by Yingying Zeng (2122864)

Image1_Comprehensive Analysis of Expression and Prognostic Value of MS4As in Glioma.TIFF by Yingying Zeng (2122864)

Trends of uptake of delivery by CS and trends of the uptake of maternity incentives among women who had at least a live birth and gave birth in HFs one year prior to the three most... by Resham B. Khatri (10949429)

An Allosteric Modulator of RNA Binding Targeting the N‑Terminal Domain of TDP-43 Yields Neuroprotective Properties by Niloufar Mollasalehi (9511076)

“…<i>In silico</i> docking of 50K compounds to the NTD domain of TDP-43 identified a small molecule (nTRD22) that is bound to the N-terminal domain. …”

This figure shows the results for 200 epochs at each lookback starting from 1 to 500. by Muhammad Muneeb (3244095)

Modulating Cytotoxicity with Lego-like Chemistry: Upgrading Mitochondriotropic Antioxidants with Prototypical Cationic Carrier Bricks by Sofia Benfeito (4345591)

“…Although the lipophilic triphenylphosphonium (TPP⁺) cation is widely used to target antioxidants to mitochondria, TPP⁺-based derivatives have shown cytotoxicity in several biological <i>in vitro</i> models. We confirmed that <b>Mito.TPP</b> is cytotoxic to both human neuronal (SH-SY5Y) and hepatic (HepG2) cells, decreasing intracellular adenosine triphosphate (ATP) levels, leading to mitochondrial membrane depolarization and reduced mitochondrial mass after 24 h. …”

IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and <i>in vivo</i> half-life: Potential application in combination with broad neutralizing antibodi... by Wenwen Bi (8086730)

“…To overcome this limitation, we developed a new strategy to extend the <i>in vivo</i> half-life of a short HIV-1 fusion inhibitory peptide, CP24, by fusing it with the human IgG Fc-binding peptide (IBP). …”

Association between the posterior part of the circle of Willis and the vertebral artery hypoplasia by Virginija Gaigalaite (7378229)

“…With the increasing degree of VAH, the proportion of FCW increases, while the proportion of absence/hypoplastic of both PCoA decreases.</p></div>…”

Image5_Vitamin D and Lipid Profiles in Postmenopausal Women: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.tif by Weiting Liu (8377335)